The present study provides proof of the concept showing that aneuploid CD31− CTCs and CD31+ CTECs may function as a pair of cellular circulating tumor biomarkers in predicting and prognosticating NSCLC patients subjected to anti‐angiogenic combination therapy. This evidence concerns the gene PECAM1 and neoplasm.